“To our knowledge, this is the first reported case of sustained control of HIV in a child enrolled in a randomized trial of ART interruption following treatment early in infancy,” coleader of the reported case and CHER trial, Amy Violari, FCPaed, said in the press release. Caroline Tiemessen, PhD, whose laboratory is analyzing the child’s immune system, added that they believe that there may be other factors at play here in addition to the early ART that resulted in HIV remission. They hope to find out more by further studying the child.
This is not the first time that a child who received treatment early on in their lives achieved prolonged control of the virus after stopping treatment. The “Mississippi baby
,” who was born with the virus in 2010, received treatment just 30 hours after birth, and stopped the treatment at about 18 months of age. This child was able to control the virus without any drugs for a whopping 27 months before it was detected
in her blood. Researchers reported another similar case in 2015, when a French child
born with the virus in 1996 started treatment at 3 months of age and stopped treatment between 5.5 and 7 years of age. That child achieved prolonged control of the virus without drug assistance “more than 11 years later,” according to the press release.
“Further study is needed to learn how to induce long-term HIV remission in infected babies,” Anthony Fauci, MD, director of the NIAD, of the National Institutes of Health said in the press release. “However, this new case strengthens our hope that by treating HIV-infected children for a brief period beginning in infancy, we may be able to spare them the burden of life-long therapy and the health consequences of long-term immune activation typically associated with HIV disease.”
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.